Search results
Results From The WOW.Com Content Network
Splenic infarction is a condition in which blood flow supply to the spleen is compromised, [1] leading to partial or complete infarction (tissue death due to oxygen shortage) in the organ. [2] Splenic infarction occurs when the splenic artery or one of its branches are occluded, for example by a blood clot .
Antiplatelet drugs are widely used in primary and secondary prevention of thrombotic disease, especially myocardial infarction and ischemic stroke. [ 1 ] Antiplatelet therapy with one or more of these drugs decreases the ability of blood clots to form by interfering with the platelet activation process in primary hemostasis .
Biotechnology developments then paved way for the first successful synthetic anticoagulants including hirudin. [6] The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [3] [14]
[1] [2] Antithrombotics can be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a dangerous blood clot (acute thrombus). In the U.S., the American College of Chest Physicians publishes clinical guidelines for clinicians for the use of these drugs to treat and prevent a variety of diseases. [citation ...
An anticoagulant, commonly known as a blood thinner, is a chemical substance that prevents or reduces the coagulation of blood, prolonging the clotting time. [1] Some occur naturally in blood-eating animals, such as leeches and mosquitoes, which help keep the bite area unclotted long enough for the animal to obtain blood.
There are, however, some novel oral anticoagulant drugs that are currently in early and advanced stages of clinical development. Most of those drugs are in the class of direct factor Xa inhibitors , but there is one DTI called AZD0837, [ 26 ] which is a follow-up compound of ximelgatran that is being developed by AstraZeneca.
Adenosine diphosphate receptor inhibitors are a drug class of antiplatelet agents, used in the treatment of acute coronary syndrome (ACS) or in preventive treatment for patients who are in risk of thromboembolism, myocardial infarction or a stroke. These drugs antagonize the P2Y 12 platelet receptors and therefore prevent the binding of ADP to ...
The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin.The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters. [1]